OncoMatch/Clinical Trials/Blood Cancer — Myelodysplastic (MDS)
Blood Cancer — Myelodysplastic (MDS) Clinical Trials
OncoMatch filters Blood Cancer — Myelodysplastic (MDS) trials by the molecular markers that determine eligibility — TP53, SF3B1, ASXL1, DNMT3A, and more. Enter your biomarker results to see only the trials you may qualify for.
Compare eligibility criteriaAbout Blood Cancer — Myelodysplastic (MDS) trials
What goes into your bone marrow biopsy matters a lot for MDS trial eligibility. Most trials need a recent biopsy with cytogenetics and a myeloid mutation panel. The genes tested usually include TP53 and SF3B1 (the two with the largest impact on prognosis), the epigenetic regulators DNMT3A, TET2, ASXL1, and EZH2, the IDH genes (IDH1 and IDH2), and RUNX1. Trials opened in the last few years often want IPSS-M (molecular) risk results, while older trials still use IPSS-R. If your bone marrow is more than a few months old, ask your oncologist whether trials will accept it or want a fresh sample.
Trials open right now fall into a few groups. HMA combination trials add new agents to azacitidine or decitabine for higher-risk disease. Post-HMA trials enroll patients who progressed on or didn't respond to first-line treatment. A growing set targets TP53-mutated MDS specifically. This is the highest-priority subgroup right now because outcomes on standard therapy remain poor. Mutation-targeted trials in IDH1 and IDH2 overlap with the AML side, and patients with high blast counts may also qualify for AML trials. Lower-risk MDS has fewer open trials, and most focus on erythroid response.
Beyond biomarkers, MDS trial eligibility typically depends on a few clinical features. Blast percentage at screening: caps of 5%, 10%, or 20% are common depending on cohort design. Risk category by IPSS-R or IPSS-M. Prior HMA treatment is usually a defining factor: required for post-HMA trials, excluded for first-line. Transfusion dependency matters most for low-risk trials. Most trials want ECOG performance status of 0-2.
Biomarkers tested in Blood Cancer — Myelodysplastic (MDS) trials
These are the molecular markers most commonly required or evaluated in Blood Cancer — Myelodysplastic (MDS) eligibility criteria. OncoMatch extracts them from each trial's protocol and matches them against your test results.
Top recruiting Blood Cancer — Myelodysplastic (MDS) trials
Ranked by phase and number of US sites. See all trials matched to your profile →
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Taiho Oncology, Inc.
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Takeda
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Takeda
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Celgene
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
Institut de Recherches Internationales Servier
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
M.D. Anderson Cancer Center
How OncoMatch finds Blood Cancer — Myelodysplastic (MDS) trials for you
AI reads the protocol
Every Blood Cancer — Myelodysplastic (MDS) trial on ClinicalTrials.gov has eligibility criteria written for regulators. OncoMatch uses large language models to extract the structured requirements — biomarkers, stage, prior therapy, and more — from that text.
You enter your results
Select Blood Cancer — Myelodysplastic (MDS) and mark your biomarker results — TP53, SF3B1, ASXL1 — as positive, negative, or not tested. Your data never leaves your device.
See only relevant trials
Results filter instantly. Each trial shows exactly which criteria you meet, which you don't, and which need more information. Bring the list to your oncologist.